Stockreport

Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate

Kymera Therapeutics, Inc.  (KYMR) 
PDF KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate  Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from G [Read more]